Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment
Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment
All the guidelines suggest that metformin as the basis of type 2 diabetes medication, and
 evidence is sufficient.At the same time the basal insulin injection once a day are more and
 more widely used in diabetes patients in China.

 This study aims to evaluate the efficacy and safety of adding glimepiride to type 2 diabetes
 patients with inadequate glycemic control with combined therapy of metformin and basal
 insulin.
Inclusion Criteria:

 -  Understand the whole test process, voluntary and signed informed consent form

 -  Men and women aged 35 to 70 years old

 -  20≤BMI<35 Kg/m2

 -  Diagnosed with type 2 diabetes

 -  Undergoing metformin(Dose not less than 1000 mg/day)in combination with basal insulin
 injection once a day

 -  HbA1c7.0-11%

 -  Patients should be able to self blood glucose monitoring

 Exclusion Criteria:

 -  sulfonylureas,glinides,TZDs use within 3 months before the study

 -  Pregnant or lactating women

 -  A history of ketoacidosis

 -  Allergy to sulfonylureas or sulfa drug patients

 -  Apparent dysfunction of liver and kidney patients(ALT>2 times upper normal limit,serum
 creatinine>1.2 times upper normal limit)

 -  Poor blood pressure control(systolic pressure>180mmHg or diastolic blood
 pressure>110mmHg)

 -  heart disease,cardiac insufficiency,unstable angina pectoris,ECG indicates left
 ventricle hypertrophy,severe anemia(Hb<9.0g/d1)

 -  Severe diabetic nerve complications(ulcer of lower limb,neurogenic bladder)

 -  BMI<20 orBMI≥35kg/m2

 -  Alcohol or drug abuse ,or can't collaborate due to mental disorder

 -  Digestion and absorption function obstacle or Other endocrine disorders

 -  Other chronic diseases required long-term glucocorticoid treatment